Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
32.52
+0.29 (0.90%)
Apr 29, 2025, 4:00 PM EDT - Market closed
Janux Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Janux Therapeutics stock have an average target of 94.29, with a low estimate of 41 and a high estimate of 200. The average target predicts an increase of 189.94% from the current stock price of 32.52.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2025.
Analyst Ratings
The average analyst rating for Janux Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 3 |
| Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 10 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +115.25% | Mar 3, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $62 → $41 | Hold | Maintains | $62 → $41 | +26.08% | Feb 28, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $200 | Buy | Reiterates | $200 | +515.01% | Dec 11, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $42 → $62 | Hold | Maintains | $42 → $62 | +90.65% | Dec 4, 2024 |
| Stifel | Stifel | Strong Buy Maintains $70 → $115 | Strong Buy | Maintains | $70 → $115 | +253.63% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
2.15M
from 10.59M
Decreased by -79.67%
Revenue Next Year
7.55M
from 2.15M
Increased by 250.58%
EPS This Year
-1.99
from -1.28
EPS Next Year
-2.44
from -1.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | 49.9M | 35.3M | ||
| Avg | 2.2M | 7.5M | 10.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.8% | 2,216.5% | 367.9% | ||
| Avg | -79.7% | 250.6% | 42.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.24 | -1.47 | -1.86 | ||
| Avg | -1.99 | -2.44 | -3.27 | ||
| Low | -3.25 | -4.74 | -5.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.